Farletuzumab

DB05595InvestigationalProtein Based Therapies

Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

Mechanism: Pharmacologically active on Folate receptor alpha
Curator reviewed
Primary indication: Investigated for use/treatment in ovarian cancer.Curator reviewed
Code names: MORAb-003

Resolves to

Compound

UNII2O09BG0OWACAS896723-44-7KEGGD09343

Targets

P15328FOLR1

What you can answer from here — as of January 14, 2023

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

421Drug interactionsStructured to mechanism, not free text

12Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Farletuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account